MX2024005342A - Análogos de auristatina novedosos e inmunoconjugados de estos. - Google Patents

Análogos de auristatina novedosos e inmunoconjugados de estos.

Info

Publication number
MX2024005342A
MX2024005342A MX2024005342A MX2024005342A MX2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A
Authority
MX
Mexico
Prior art keywords
immunoconjugates
novel auristatin
novel
auristatin analogues
analogues
Prior art date
Application number
MX2024005342A
Other languages
English (en)
Spanish (es)
Inventor
Richard Hui Li
Dong Jun Lee
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of MX2024005342A publication Critical patent/MX2024005342A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024005342A 2021-11-03 2022-11-02 Análogos de auristatina novedosos e inmunoconjugados de estos. MX2024005342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US202163295476P 2021-12-30 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
MX2024005342A true MX2024005342A (es) 2024-09-27

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005342A MX2024005342A (es) 2021-11-03 2022-11-02 Análogos de auristatina novedosos e inmunoconjugados de estos.

Country Status (9)

Country Link
EP (1) EP4426714A4 (https=)
JP (1) JP2024540402A (https=)
KR (1) KR20240110584A (https=)
AU (1) AU2022380491A1 (https=)
CA (1) CA3236944A1 (https=)
IL (1) IL312533A (https=)
MX (1) MX2024005342A (https=)
TW (1) TW202334176A (https=)
WO (1) WO2023081230A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
CA3236944A1 (en) 2023-05-11
EP4426714A1 (en) 2024-09-11
AU2022380491A1 (en) 2024-05-30
TW202334176A (zh) 2023-09-01
IL312533A (en) 2024-07-01
KR20240110584A (ko) 2024-07-15
WO2023081230A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
JP2024540402A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
UA130338C2 (uk) Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CO2022019316A2 (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
PE20221417A1 (es) Degradadores bifuncionales de brd9 y sus metodos de uso
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
AR123685A1 (es) Antagonistas del mrgx2
PA8583101A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
CL2025002872A1 (es) Anticuerpos anti-cd19 y estructuras car-t
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2024005342A (es) Análogos de auristatina novedosos e inmunoconjugados de estos.
DOP2025000220A (es) Compuestos bifuncionales capaces de degradar receptores de andrógenos
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
CO2025002334A2 (es) Derivados arilos tricíclicos, y composiciones y métodos de los mismos